BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) granted inducement restricted stock units to six newly hired employees covering an aggregate of 61,750 shares, effective May 1, 2026.

The RSUs were issued under Nasdaq Listing Rule 5635(c)(4), vest in four equal annual installments beginning on the one-year anniversary, and are subject to the Inducement Equity Incentive Plan and individual RSU agreements.

News Market Reaction – BCRX

-1.85%

22 alerts

-1.85% Session close to close

-9.9% Trough in 2 hr 16 min

$2.29B Market Cap

0.3x Rel. Volume

In the May 5 session, BCRX declined 1.85%, reflecting a mild negative market reaction. Argus tracked a trough of -9.9% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details inducement grants of 61,750 RSUs to six new employees under Nasdaq Listing...

Analysis

This announcement details inducement grants of 61,750 RSUs to six new employees under Nasdaq Listing Rule 5635(c)(4), vesting over four years and tied to continued service. It follows a similar 65,850-RSU inducement disclosed on March 2, 2026, underscoring ongoing use of equity for recruitment. Against recent strategic moves, such as the European navenibart license with $70M upfront and up to $275M in milestones, these grants reflect routine compensation rather than a shift in strategy.

Key Figures

New hire count: 6 employees Inducement RSUs: 61,750 shares Grant date: May 1, 2026 +1 more

4 metrics

New hire count 6 employees Newly-hired employees receiving inducement RSUs

Inducement RSUs 61,750 shares Aggregate RSUs granted as of May 1, 2026

Grant date May 1, 2026 RSU grant date for inducement awards

Vesting schedule 4 equal annual installments RSUs vest over four years, starting one year after grant

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Licensing agreement	Positive	+0.1%	European license for navenibart with upfront, milestone payments and royalties.
Apr 28	Conference appearances	Neutral	-0.5%	Investors informed of May and June 2026 healthcare conference presentations.
Apr 15	Earnings date notice	Neutral	-2.4%	Announcement of timing for first quarter 2026 results and conference call.
Apr 06	Leadership appointment	Positive	+5.0%	Hiring of new Chief R&D Officer linked to pipeline and launch preparation.
Mar 04	Inducement RSU grants	Neutral	-1.4%	Prior inducement RSUs of 65,850 shares to six new employees under Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows positive strategic news (licensing, senior R&D hire) coinciding with gains, while administrative or compensation-related updates (conference schedules, inducement grants, earnings date) often saw modest declines.

Recent Company History

Over the last two months, BioCryst announced a European licensing deal for navenibart with upfront payments of $70M and up to $275M in milestones, presented upcoming investor conference appearances, and scheduled its Q1 2026 results. It also appointed a new Chief R&D Officer and previously reported inducement RSU grants on March 2, 2026. Those prior inducement grants of 65,850 RSUs were followed by a -1.38% move, framing today’s similar RSU announcement as part of an ongoing hiring and equity compensation pattern.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement equity incentive plan

3 terms

restricted stock units financial

"granted six newly-hired employees restricted stock units (RSUs) covering an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement equity incentive plan financial

"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"

An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What did BioCryst (BCRX) announce on May 5, 2026 about inducement grants?

BioCryst granted RSUs totaling 61,750 shares to six new hires as of May 1, 2026. According to the company, the awards are inducements under Nasdaq Listing Rule 5635(c)(4) and follow the terms of its Inducement Equity Incentive Plan and RSU agreements.

How do the BioCryst (BCRX) RSUs vest for the May 1, 2026 grant?

The RSUs vest in four equal annual installments starting on the one-year anniversary of the grant. According to the company, each installment is subject to the new employee's continued service at BioCryst at each vesting date.

Are BioCryst's May 2026 RSU grants compliant with Nasdaq rules?

Yes, the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to the company, the awards are structured as inducements permitted by that rule for newly hired employees.

What plan governs the BioCryst (BCRX) inducement RSU awards granted May 1, 2026?

The RSUs are subject to BioCryst's Inducement Equity Incentive Plan and individual restricted stock unit agreements. According to the company, those documents set the terms, conditions, and vesting mechanics for the awards.

Will the May 2026 RSU grants to six employees immediately dilute BCRX shares?

The RSUs represent potential future issuance of 61,750 shares rather than immediate dilution. According to the company, shares will be issued only as units vest and subject to plan terms and continued service.